

# 2016 vs 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain

The [2016 CDC Clinical Practice Guideline for Prescribing Opioids for Chronic Pain](#) addresses concerns about unintended harm from rigid prescribing limits. The updated [2022 Clinical Practice Guideline for Prescribing Opioids for Pain](#) includes a patient-centered approach for prescribing. The table below describes the major differences between the two guidelines.

| Criteria   | 2016 Version  | 2022 Version  |
|--|---|---|
| Scope and Intent   | Focuses on chronic pain (outside of cancer, palliative, and end-of-life care).  | Includes acute, subacute, and chronic pain. Still excludes cancer, palliative, and end-of-life care.                  |
| Opioid Dose Limits   | Suggests a strict upper limit of 90 MME/day and encourages staying below 50 MME/day when possible.  | Removes strict limits. Still recommends caution at 50 MME/day and extra precaution above 90 MME/day.                  |
| Duration for Acute Pain  | Recommends a <7/day supply in most cases; often <3 days.  | No specific day limit; encourages lowest effective dose for shortest duration.  |
| Tapering Guidance  | Emphasizes reducing dose when risks outweigh benefits but lacks recommendations on how to taper.  | Provides stronger guidance on patient-centered tapering, avoiding rapid or forced tapers, and shared decision-making. |
| Non-Opioid Options   | Strongly encourages non-opioid treatments without providing detailed options.   | Expands discussion on multimodal and non-opioid therapies, emphasizing individualized care.                           |
| Clinical Decision Making   | Specific dosage recommendations which do not account for individual patient scenarios, leading to concerns of misapplication and unintended patient harm. | Promotes patient-centered language, discouraging one-size-fits-all policies and unintended consequences.              |
| Risk Considerations  | Focuses on opioid-related harms (e.g., drug poisoning and addiction).   | Balances opioid risks with risks of undertreated pain and harm from abrupt discontinuation.                           |
| Prescription Drug Monitoring (PDMP) and Urine Drug Testing (UDT) | Recommends checking PDMP and using UDT without frequency recommendations.   | Recommends checking PDMP and using UDT with an emphasis on clinical judgment rather than strict rules.                |

